Health(y) Inc: Top private hospitals see spurt in per-bed revenue

India's leading private hospitals are experiencing a significant revenue surge per bed, driven by advanced high-tech treatments and increased insurance coverage. This trend, reflected in 2024-25 data, shows a 23% rise in average daily revenue per bed, indicating a broader shift towards specialized and expensive medical procedures becoming more accessible to patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BUgFR4v
via IFTTT

Read More

Intense Lilly, Novo rivalry throws India weight-loss drug race wide open

Eli Lilly and Novo Nordisk are in a race to dominate India's booming obesity drug market. They are using aggressive marketing, doctor outreach and partnerships. Lilly's Mounjaro launched early and is leading sales. Novo Nordisk is cutting prices and launching Ozempic. Generic versions are expected next year, intensifying the competition in this price-sensitive market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dr5jXoy
via IFTTT

Read More

Bristol Myers lines up many launches for India with 'AI' speed

Bristol Myers Squibb sees India as a major growth driver. The company is investing heavily in AI to speed up drug launches and improve doctor engagement. New medicines for heart conditions and cancer are coming to India. This strategic move aims to boost sales and prepare for patent expirations. India is becoming a hub for AI innovation for the company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t7Dn5Xl
via IFTTT

Read More

Customs duty waiver likely for SEZ-made drugs sold locally

India may soon waive customs duty on medicines produced in special economic zones for local sale. This move aims to reduce costs and increase the availability of essential drugs and vaccines within the country. The proposal could be part of the upcoming Union budget.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r0qA4Gm
via IFTTT

Read More

Bharat Biotech, Biofabri in tech transfer deal for TB vaccine

MTBVAC, the TB vaccine, has undergone Phase I and II clinical trials in India. The vaccine has demonstrated safety and immunogenicity. Based on the initial results, Bharat Biotech is preparing for a pivotal Phase III vaccine efficacy study. It will start recruiting participants in the first quarter of 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eK3d1uL
via IFTTT

Read More

Be patient... prices of your medicines may come down soon

Indian medicines may become more affordable as China's active pharmaceutical ingredient (API) prices have dropped significantly, by 35-40%. This reduction in manufacturing costs for generic drug makers is expected to translate into lower medicine prices for consumers. Experts anticipate further price declines in the coming months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GaHfzd3
via IFTTT

Read More

Park Medi World to acquire KP Institute of Medical Sciences for ₹245 crore

Park Medi World is acquiring KP Institute of Medical Sciences for Rs 245 crore. This all-cash deal will add 360 beds to Park Medi World's network. The acquisition aims to strengthen the hospital chain's presence in North India. Integration is expected to improve clinical programs and efficiency. The company anticipates significant value addition soon after the transaction is complete.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oVGSnRO
via IFTTT

Read More

Emcure Pharma launches weight loss drug Poviztra in India

Emcure Pharmaceuticals has launched Poviztra, a semaglutide injection for weight loss, becoming the first Indian company to exclusively distribute Novo Nordisk's medication. Available in a once-weekly pen device, Poviztra is indicated for chronic weight management in adults with obesity and at least one weight-related comorbidity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VHFAsre
via IFTTT

Read More

Motilal Oswal Alternates invests $72 million in Sensa Core Medical

Motilal Oswal Alternates has invested $72 million in Sensa Core, a Hyderabad-based medical devices company. Sensa Core, a leader in electrolyte analyzers, exports to over 78 countries and manufactures glucometers and hemoglobin meters. This investment supports India's growing medical device sector and aims to improve healthcare access through local manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8nfevty
via IFTTT

Read More

Granules unit gets USFDA nod for generic drug

Granules India has secured tentative approval from the USFDA for its generic ADHD medication. This approval is for Amphetamine extended-release orally disintegrating tablets. The drug is a generic version of Adzenys XR-ODT. It will be manufactured at Granules' US facility. The medication treats Attention Deficit Hyperactivity Disorder. This move strengthens Granules' presence in the Central Nervous System therapeutic area.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2xWXZ1P
via IFTTT

Read More

Young doctors free to go abroad, but can no longer say facilities lacking in India: JP Nadda

Asserting that the country's medical education landscape has transformed under Prime Minister Narendra Modi, the Union health minister said the number of All India Institute of Medical Sciences (AIIMS) in the country has gone up to 23.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/znLhWuT
via IFTTT

Read More

Fortis to acquire Bengaluru’s People Tree Hospitals for Rs 430 crore

Fortis Healthcare Limited is set to acquire TMI Healthcare Private Limited, which operates People Tree Hospitals in Bengaluru, for Rs 430 crore. The deal includes the hospital, its infrastructure, land, and an adjacent parcel. This strategic acquisition aims to expand Fortis's presence in the region, leveraging People Tree's established multispecialty services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gRlxm14
via IFTTT

Read More

Centre draws a price line to curb cheap pharma imports

India has set a minimum import price for essential drug ingredients. This move aims to protect domestic manufacturers from aggressive pricing by Chinese companies. The restrictions will be in place until November 2026. Some experts worry this could increase medicine costs for patients. The government launched a scheme to boost local production and reduce reliance on China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nxuQKYh
via IFTTT

Read More

Cipla, Pfizer ink partnership for exclusive marketing of four brands in India

Pfizer India and Cipla Limited have announced a strategic partnership where Cipla will exclusively market and distribute four of Pfizer's key brands in India. This collaboration aims to leverage Cipla's extensive distribution network to enhance patient access to essential medicines like Corex Dx, Dolonex, Neksium, and Dalacin C across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S3hPJzi
via IFTTT

Read More

Centre weighs new law to regulate medical research

In an ambitious step forward, India is drafting a new law to enhance medical research practices. This forthcoming Bill seeks to establish robust ethical benchmarks while prioritizing safety and quality. At the behest of the Prime Minister's Office, the Indian Council of Medical Research is spearheading this initiative.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f01svbQ
via IFTTT

Read More

USFDA issues Form 483 with 5 observations to Aurobindo Pharma's Andhra unit

Aurobindo Pharma said the USFDA issued a Form 483 with five procedural observations after inspecting Unit-IV of its subsidiary APL Healthcare in Andhra Pradesh from December 8–17, 2025. The company said it will respond within stipulated timelines and remains committed to quality standards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xvuwkpa
via IFTTT

Read More

FDA cancels licences of 13 medical stores, suspends 32 over sale of intoxicant tablets in Nanded

Nanded's medical stores face strict action. The Maharashtra Food and Drug Administration has cancelled licenses of thirteen stores and suspended thirty-two. This action follows the alleged sale of intoxicant tablets without a doctor's prescription. The FDA investigated forty-eight stores, finding violations of the Drugs and Cosmetics Act.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bs9RBZM
via IFTTT

Read More

US FDA issues 'Official Action Indicated' status to Sun Pharma’s Baska facility after inspection

Sun Pharmaceutical Industries Ltd announced that its Baska manufacturing facility has been classified as Official Action Indicated (OAI) by the US FDA following a recent inspection. Despite this classification, the company confirmed that supplies to the US market from the plant will continue uninterrupted. Sun Pharma stated it will collaborate with the regulator to ensure full compliance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7OhGSwU
via IFTTT

Read More

India's pharma exports cross $30 billion: Rajesh Agrawal

India's pharmaceutical exports have surpassed $30 billion in FY25. The nation stands as a trusted global supplier of quality and affordable medicines. India is the third largest producer by volume and 14th by value. Medicines reach over 200 markets. The domestic market is projected to reach $130 billion by 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jKa36cP
via IFTTT

Read More

Oral cancer preventable if detected early, says Kidwai Institute cancer expert

Most oral cancer patients in India seek out medical assistance at stage three or four largely due to ignorance and delayed diagnosis. If dentists identify and refer cases at an early stage, patients can receive timely treatment, which will improve the chances of their survival, Dr Nadimul Hodasaid.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eyjBu7I
via IFTTT

Read More

Novartis bets big on India, builds its largest global R&D hub outside Switzerland

Novartis is significantly expanding its biomedical research and drug development operations in India, positioning it as a key global hub outside Switzerland. With over 9,000 employees, Indian teams now contribute to nearly every Novartis molecule in late-stage development, driving high-value, science- and data-led innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lYqgXyR
via IFTTT

Read More

Reliance eyes Jio-style disruption in genomics with sub-Rs 1,000 tests

The energy-to-retail conglomerate is leveraging Strand Life Sciences for its entry into the emerging areas of specialised healthcare diagnostics and genomic sciences. Reliance had acquired the Bengaluru-based company for ₹393 crore in 2021.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LZk9Cp5
via IFTTT

Read More

Supriya Lifescience targets Rs 1,600-cr revenue in three years on capacity expansion

Supriya Lifescience plans to reach Rs 1,600 crore revenue in three years. New facilities in Lote MIDC and Ambernath will drive this growth. The company focuses on niche, complex APIs, moving away from mass-volume products. New product launches and contract manufacturing tie-ups are also planned. Supriya Lifescience is debt-free, funding expansion through internal accruals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QerLS2v
via IFTTT

Read More

IHH Healthcare to expand India capacity to 7,000 beds by 2028

IHH Healthcare is set to significantly boost its Indian capacity to approximately 7,000 beds by 2028, following a stake increase in Fortis Healthcare. This expansion, aiming for an additional 2,000 beds, will leverage synergies between Fortis and Gleneagles Healthcare India to enhance patient care and operational efficiency across its 35 hospitals nationwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TwUqnoX
via IFTTT

Read More

Why are so many Indian hospitals rushing to the market?

India's healthcare sector is poised for a significant IPO boom in 2026, with hospitals and allied services expected to raise Rs 20,000 crore. This surge is driven by improving financials, strong demand due to underpenetration, and private equity backing. Specialty care and medical tourism also fuel this growth, making public markets a strategic avenue for expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4u2RrEF
via IFTTT

Read More

Trial by fire: Over 60% of pharma SMEs may be forced to shut shop

India is estimated to have about 12,000 drug manufacturing units. The units that risk being shut down account for about Rs 75,000 crore of India's Rs 2.5 lakh crore domestic drug market, the executives said. This may result in shortages of antibiotics, anti-hypertensives, anti-inflammatory medicines, analgesic, anti-cough and cold tablets, diabetes drugs and general medicines, among others, said a pharma industry expert, speaking on the condition of anonymity. "The shortages of medicines will be seen across the country. Many of these units also cater to government supplies along with supplies to tier-II and tier-III cities and exports."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZywaBmQ
via IFTTT

Read More

Lords Mark Industries Ltd.–Renalyx approved to manufacture Class C AI-based haemodialysis machines; earns global CE marking

Lords Mark Industries Ltd. has achieved a significant feat by securing a CDSCO license to produce Class C AI-based smart haemodialysis machines, bolstering India's healthcare tech self-reliance. This innovation, also CE-marked, signifies a global leap in advanced renal care, positioning India as a leader in sophisticated medical equipment manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rm47NML
via IFTTT

Read More

No scientific link found between COVID-19 vaccination, sudden deaths in young adults: AIIMS study

Sudden death in young adults is a significant concern requiring targeted public health strategies, the study said, underlying coronary artery disease remains the leading cause and that respiratory and unexplained deaths warrant further investigation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4EZCQJu
via IFTTT

Read More

Delhi to run 11 hospitals under PPP model, add over 10,000 beds

Delhi government is moving forward with a plan to operate eleven government hospitals through a public-private partnership. Most of these hospitals are currently under construction.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/D9YRGf1
via IFTTT

Read More

Himachal drug cos under stop orders found operational

Himachal Pradesh's drug regulation bodies came across a concerning trend: numerous pharmaceutical companies were found to be operating illicitly, despite official directives to cease manufacturing after failing quality evaluations. Inspections indicated these firms may not have stopped production as mandated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yanSpsX
via IFTTT

Read More

Novo Nordisk bets on cheaper Ozempic to dominate India’s booming weight-loss market

Novo Nordisk has launched Ozempic in India at a competitive price, aiming to capture a significant share of the growing weight-loss market. Leveraging its established dominance in diabetes care and insulin leadership, the company seeks to accelerate adoption of its GLP-1 therapy, positioning it against rivals like Eli Lilly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gNUOtVo
via IFTTT

Read More

Novo Nordisk brings blockbuster weight-loss drug Ozempic to India

Danish drugmaker Novo Nordisk has launched its popular diabetes drug Ozempic in India. The drug is now available at a starting price of Rs 2,200. India has a significant number of people with type 2 diabetes and rising obesity. This makes it a key market for global drugmakers. Ozempic is a weekly injectable treatment for type 2 diabetes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tvbRzVm
via IFTTT

Read More

Delhi HC allows Dr. Reddy’s to export weight-loss drug semaglutide, calls Novo Nordisk’s case ‘weak’

The Delhi High Court declined to stay a single-judge order allowing Dr. Reddy's to export its semaglutide, observing Novo Nordisk's appeal presented a weak case. This decision permits Dr. Reddy's to supply the drug to countries without Novo Nordisk's patent protection, while the broader legal dispute over intellectual property continues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zfiOv8p
via IFTTT

Read More

Glenmark to launch generic medication in US

Glenmark Pharmaceuticals will launch a new generic medication in the United States this month. This drug treats anaemia. It also prevents side effects from certain medications. Glenmark Pharmaceuticals Inc. USA will distribute the Leucovorin Calcium for Injection USP.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6NU7nBq
via IFTTT

Read More

Cipla launches drug for obesity, diabetes

Cipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now available in India. Yurpeak aims to address two significant health challenges in the country. Cipla is collaborating with Eli Lilly for this innovative treatment. The drug will be offered in multiple strengths.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GTy1s35
via IFTTT

Read More

Zydus Lifesciences introduces biosimilar to protect bone health in cancer patients

Zydus Lifesciences has launched Zyrifa, a Denosumab biosimilar, for treating osteoporosis and preventing skeletal complications in cancer patients. Priced at Rs 12,495, the drug aims to improve access and affordability for patients with bone metastases from various cancers. This initiative supports patients in retaining mobility during their cancer treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qgTzBUI
via IFTTT

Read More

Delhi HC allows Sun Pharma to manufacture, export its own weight loss drug

The Delhi High Court has allowed Sun Pharma to manufacture and export its version of semaglutide, the diabetes and anti-obesity drug made by Novo Nordisk as Wegovy. However, the court barred Sun from selling the drug in India until March 2026, when Novo Nordisk’s secondary patent expires. Sun must file an affidavit and export account details, with the case next heard on February 19.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G2UScZI
via IFTTT

Read More

'Safeguards' slowing down access to breakthrough drugs in India

New drugs are not reaching low and middle income countries. A study shows many medicines take years to become accessible globally. India's regulatory system needs to mature for quicker access to breakthrough therapies. Stronger intellectual property protection and global standardisation are key. This will help reduce delays in drug availability for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zm562ih
via IFTTT

Read More

Telangana’s loss is Andhra’s gain as pharma companies expand in Kurnool

Sigachi Industries and Virupaksha Organics are relocating expansion projects to Andhra Pradesh. They will establish new manufacturing units in Kurnool district's Orvakal Industrial Park. This move follows Telangana's decision to abandon its Pharma City plan.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HoI8ZSY
via IFTTT

Read More

Respiratory drug sales peak in November amid worsening AQI

India's air quality decline is boosting medicines for breathing problems. The respiratory drug market grew 8% last month, a rise from previous years. This trend highlights a strong link between pollution and illness. States like Uttar Pradesh and Uttarakhand saw significant sales increases for asthma and COPD treatments. Antihistamine use also climbed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xI32Cmw
via IFTTT

Read More

Dr Reddy’s inks licensing deal to sell Immutep’s cancer drug

Dr. Reddy's Laboratories has secured an exclusive licensing agreement with Immutep to manufacture, develop, and distribute the Australian company's cancer therapy, eftilagimod alfa. This significant deal, valued at up to $350 million, grants Dr. Reddy's distribution rights across most global markets, excluding North America, Europe, Japan, and Greater China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KnlBJLy
via IFTTT

Read More

ET Exclusive | Biologics merger with Biocon most value-accretive option: Kiran Mazumdar Shaw

Biocon is fully integrating Biocon Biologics, valuing its biosimilar business at $5.5 billion. This move removes debt concerns and improves financial health. The combined entity will leverage synergies across manufacturing, R&D, and commercial operations. This integration aims to accelerate launches in major markets and unlock significant growth opportunities for the unified global player.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rvdhy2q
via IFTTT

Read More

Biocon to make Biocon Biologics a wholly owned subsidiary

Biocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Biocon will acquire remaining stakes through a share swap. The deal values Biocon Biologics at $5.5 billion. This integration aims to streamline operations and enhance strategic focus.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CZqtSm5
via IFTTT

Read More

Abbott asks stockists to buy only from authorised suppliers

Spurious medicines were seized in Puducherry, prompting drug maker Abbott Healthcare to warn stockists. They must buy only from authorized suppliers. The government alerted the Drug Controller General of India about the circulation of fake drugs. The All India Organisation of Chemists and Druggists issued an advisory for safe business practices. This is a serious trade alert.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/npGh9NW
via IFTTT

Read More

Lupin gets USFDA nod for multiple sclerosis drug

Drug maker Lupin has secured approval from the US health regulator for its generic multiple sclerosis treatment. The company received tentative approval from the USFDA for Siponimod Tablets. This new product will be manufactured at Lupin's Pithampur facility. Siponimod Tablets are bioequivalent to Mayzent tablets and treat relapsing forms of multiple sclerosis in adults.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fWTzvcA
via IFTTT

Read More

AI and technology tackling India’s growing stroke crisis: Early detection and prevention take centre stage

India faces a mounting crisis with a 51% rise in stroke cases over the last 30 years, recording 1.25 million new strokes in 2021 alone. Yet only a quarter of Indians have access to stroke-ready hospitals. Doctors at the Medtronic X EconomicTimes.com “Stroke Pe Rok” webinar agreed that creating awareness, improving primary care screening, and leveraging emerging technology must become urgent priorities to save lives and reduce stroke burden in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3K5o8sy
via IFTTT

Read More

GSK India plans big 'reinvention', MD Bhushan Akshikar reveals

GlaxoSmithKline Pharmaceuticals is planning a major comeback in India. The company aims to double its revenue to ₹8,000 crore within the next 4-5 years. This growth will be driven by a strategic shift towards specialty drugs in oncology and liver diseases. Adult vaccination is also a key focus area.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nvbyTH2
via IFTTT

Read More

NABL accreditation sets the stage for Lords Mark Microbiotech’s growth and preventive health push

Lords Mark Microbiotech, a Lords Mark Industries subsidiary, has earned NABL accreditation. This validates their diagnostic services. The company plans to open 200 labs and 2,000 collection centers nationwide in two years. They aim to become a top pathology player. An Organ Health Score offers personalized health insights. This expansion focuses on preventive healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1HWOlN9
via IFTTT

Read More

Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment

The joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to make a difference in delaying cognitive decline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qikjFVD
via IFTTT

Read More

Sun Pharma unit to invest Rs 3,000 cr on new plant in Madhya Pradesh

Sun Pharmaceutical Industries' subsidiary, Sun Pharma Laboratories Ltd, has approved a Rs 3,000 crore investment for a new greenfield formulations manufacturing facility in Madhya Pradesh. This significant expansion by the Mumbai-based drug major aims to bolster its production capabilities. The announcement comes as Sun Pharma's shares saw a slight increase on Wednesday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F76BokX
via IFTTT

Read More

India weight-loss market reset? In setback for Novo Nordisk, Dr Reddy's Lab allowed to make semaglutide

The order follows the court’s view that Novo Nordisk’s patent appears prima facie invalid -- a finding that could reshape competitive dynamics in a market valued at around Rs 850 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZcG9JDB
via IFTTT

Read More

Novo Nordisk India partners with Healthify to launch AI-enabled patient support programme

Novo Nordisk India and Healthify have launched a new programme. It offers AI-assisted lifestyle guidance for people with obesity. This partnership aims to improve patient experience and treatment results. An AI assistant will help users track nutrition throughout their treatment journey.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NrLORbi
via IFTTT

Read More

HC lets Dr Reddy's Laboratories export Semaglutide, blocks India sales till March '26

The Delhi High Court has permitted Dr Reddy's Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglutide. This decision comes amidst a patent infringement case filed by Novo Nordisk. Dr Reddy's is restricted from selling the drug within India until March 2026. The court acknowledged a valid challenge to Novo Nordisk's patent for semaglutide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/upk0RgU
via IFTTT

Read More

Jubilant Pharmova names Daniel J O'Connor as CEO of proprietary drugs biz

Jubilant Pharmova has appointed Daniel J O'Connor as the CEO of its novel drugs business. O'Connor brings over 30 years of leadership experience in biotechnology and oncology. His expertise includes creating value around differentiated, IP-rich platforms. Previously, he was CEO of Ambrx Biopharma, where his leadership led to a significant increase in company valuation and its successful acquisition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9ITnu4N
via IFTTT

Read More

Cough syrup row puts regulators on overdrive to test pharma products

Indian drug companies are significantly increasing product testing. This surge follows strict government rules and joint inspections by regulators. The focus is on ensuring quality after recent contamination issues. Testing volumes have jumped dramatically. Companies are investing in specialized equipment to detect toxic substances. This heightened vigilance aims to safeguard public health and maintain the integrity of India's pharmaceutical industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p2w1POC
via IFTTT

Read More

Wockhardt gets NDA status for novel antibiotic Zaynich

Wockhardt, an emerging powerhouse in the Indian pharmaceutical arena, has just scored a game-changing triumph! The US health regulator has given the green light to its New Drug Application for Zaynich, a cutting-edge antibiotic. This pivotal moment signifies the first occurrence of an Indian firm securing FDA acceptance for a New Chemical Entity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KYnqwyE
via IFTTT

Read More